| 摘要 |
A solid oral dosage form comprising as therapeutic agents: (a) an effective amount of valsartan or a pharmaceutically acceptable salt thereof present in an amount below or equal to 35% by weight based on the total weight of the solid oral dosage form; and (b) an effective amount of hydrochlorothiazide (HCTZ); a process of forming a solid oral dosage form; and the use of the dosage form in the manufacture of a medicament for treating hypertension, congestive heart failure, angina, myocardial infarction, atherosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, left ventricular hypertrophy, cognitive dysfunction, stroke, headache and chronic heart failure. (62) Divided out of 505863
|
